Advertisement
EXEL vs RIGL
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Buy and RIGL is a StrongBuy.
EXEL's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for EXEL turned positive on October 09, 2026. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in 34 of 43 cases over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on EXEL as a result. In 67 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in 206 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 166 of 268 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
EXEL broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.325) is normal, around the industry mean (3.162). P/E Ratio (21.091) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (6.305) is also within normal values, averaging (439.647).
RIGL in upward trend: price rose above 50-day moving average on October 19, 2026
RIGL moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 37 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on RIGL as a result. In 60 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for RIGL just turned positive on October 26, 2026. Looking at past instances where RIGL's MACD turned positive, the stock continued to rise in 31 of 36 cases over the following month. The odds of a continued upward trend are 86%.
Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where RIGL advanced for three days, in 226 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 160 of 210 cases where RIGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RIGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RIGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.253) is normal, around the industry mean (3.162). P/E Ratio (2.879) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (3.146) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
EXEL | RIGL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 3 | 63 | |
SMR RATING 1..100 | 23 | 12 | |
PRICE GROWTH RATING 1..100 | 35 | 36 | |
P/E GROWTH RATING 1..100 | 27 | 90 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RIGL's Valuation (74) in the Biotechnology industry is in the same range as EXEL (90). This means that RIGL’s stock grew similarly to EXEL’s over the last 12 months.
EXEL's Profit vs Risk Rating (3) in the Biotechnology industry is somewhat better than the same rating for RIGL (63). This means that EXEL’s stock grew somewhat faster than RIGL’s over the last 12 months.
RIGL's SMR Rating (12) in the Biotechnology industry is in the same range as EXEL (23). This means that RIGL’s stock grew similarly to EXEL’s over the last 12 months.
EXEL's Price Growth Rating (35) in the Biotechnology industry is in the same range as RIGL (36). This means that EXEL’s stock grew similarly to RIGL’s over the last 12 months.
EXEL's P/E Growth Rating (27) in the Biotechnology industry is somewhat better than the same rating for RIGL (90). This means that EXEL’s stock grew somewhat faster than RIGL’s over the last 12 months.
| EXEL | RIGL | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | N/A |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 67% | 2 days ago 83% |
| Advances ODDS (%) | 4 days ago 68% | 3 days ago 82% |
| Declines ODDS (%) | 19 days ago 59% | 9 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 57% | N/A |
| Aroon ODDS (%) | 2 days ago 62% | 2 days ago 76% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EXEL’s FA Score shows that 3 FA rating(s) are green while RIGL’s FA Score has 1 green FA rating(s).
- EXEL’s FA Score: 3 green, 2 red.
- RIGL’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EXEL’s TA Score shows that 4 TA indicator(s) are bullish while RIGL’s TA Score has 5 bullish TA indicator(s).
- EXEL’s TA Score: 4 bullish, 4 bearish.
- RIGL’s TA Score: 5 bullish, 2 bearish.
Price Growth
EXEL (@Biotechnology) experienced а +7.53% price change this week, while RIGL (@Biotechnology) price change was +6.61% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
Reported Earning Dates
EXEL is expected to report earnings on Feb 09, 2027.
RIGL is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (+0.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement